Oslo, Norway, October 22, 2021 - Lytix Biopharma, a Norwegian immune-oncology
company, today announces that the European Patent Office has granted patent no.
3229823B1 that covers the use of Lytix Biopharma's leading drug candidate
LTX-315 in combination with a chemotherapeutic agent. The US member of this
patent family has also recently been granted (patent no. 11123398B2), thus the
family is now granted in major markets, including, in addition to Europe and
USA, Japan. 
 
Dr. Øystein Rekdal, CEO of Lytix Biopharma, comments: "The grant of this
European patent is an important milestone in our Intellectual Property (IP)
strategy and further strengthens our business case, as securing IP rights is
critical for the protection of Lytix' technology platform and the long-term
value generation of the company".

For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358, 
E-mail: Oystein.Rekdal@lytixbiopharma.com 

About Lytix Biopharma 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immune-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic peptide that has
demonstrated superior abilities to induce polyclonal T-cell responses.